"At AAPS, we are committed to tackling the latest issues ?even the toughest issues ?and exposing our members to disparate points of view so they ?as the most highly trained scientists in the world ?can draw their own conclusions," said John Lisack, AAPS executive director. "With topics like cloning and biogenerics headlining this year's event, there is no more exciting and challenging time to be in the field of pharmaceutical sciences than now."
The following topics will headline this year's meeting:
Creator of "Dolly" and world-renowned scientists share insight
Making his first U.S. appearance since his book, About Dolly, hit shelves earlier this month, Dr. Ian Wilmut, the lead researcher of a team of scientists who were first to successfully clone an animal, Dolly the sheep, ten years ago, will speak about his plans to clone embryos to alter disease genes in humans. Wilmut will be joined by two other leaders in biotechnology research, Dr. Kevin Eggan of the Harvard Stem Cell Institute, where plans were just announced to create the world's first cloned human embryonic stem cells, and Dr. Burt Adelman of Biogen Idec, the company that produces the recently re-approved multiple sclerosis drug, Tysabri. The Plenary Session is Monday, June 19 from 8:30 a.m. to 11:30 a.m. at the Hynes Convention Center.
Biogenerics ?The next revolution in health care?
Generic biopharmaceutical drugs, or biogenerics, are widely available in Europe and Australia, but
'"/>
Source:American Association of Pharmaceutical Scientists